Business Context and Reporting Period
This Form 8-K, filed on December 10, 2020, reports on events occurring between December 1 and December 8, 2020, for Synaptogenix, Inc. (formerly Neurotrope Bioscience, Inc.). The filing details the consummation of a Spin-Off from Neurotrope, Inc., effective December 7, 2020. Following the separation, Synaptogenix received operating assets, liabilities, and cash in excess of $20,000,000. The company changed its name to Synaptogenix, Inc., and expects to trade on the OTCQB market under the symbol "SNPX."
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin figures for Synaptogenix as a standalone entity. Key financial data points include:
- Cash Contribution: Neurotrope contributed cash in excess of $20,000,000 (subject to adjustment) to Synaptogenix.
- Authorized Capital: 150,000,000 shares of common stock and 1,000,000 shares of preferred stock.
- Equity Incentive Plan: 1,000,000 shares of common stock reserved for the 2020 Equity Incentive Plan.
- Debt and Liquidity: Specific debt levels and liquidity ratios are not disclosed in this report.
Material Changes
The primary material change is the corporate separation from Neurotrope, Inc. Key changes include:
- Corporate Structure: Transition from a subsidiary to an independent public company with a new name and charter.
- Asset Allocation: Transfer of all operating assets and liabilities not retained by Neurotrope to Synaptogenix.
- Executive Leadership: Termination of Charles S. Ryan as CEO and appointment of Dr. Alan J. Tuchman as the new CEO and Board member.
- Security Rights: Distribution of Synaptogenix common stock to Neurotrope shareholders at a ratio of 1 share of Synaptogenix for every 5 shares of Neurotrope common stock held.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ materially from expectations due to various risks. Specific outlook items include:
- Trading Status: The company expects to begin trading on the OTCQB market under the symbol "SNPX" at a future date.
- Management Commentary: The new CEO, Dr. Tuchman, brings experience from New York Medical College and previous biotech leadership roles.
- Risks and Contingencies: The Tax Matters Agreement allocates tax liabilities between the two entities, with Neurotrope indemnifying Synaptogenix for pre-Spin-Off taxes attributable to Neurotrope.
- Unusual Items: The termination of the former CEO involved a separation package including 12 months of base salary, a $225,000 cash bonus, and COBRA coverage.
Investor Verification Checklist
- Verify the exact amount of cash contributed to Synaptogenix, as the filing states "in excess of $20,000,000, subject to adjustment."
- Confirm the specific date Synaptogenix stock begins trading on the OTCQB market under the symbol "SNPX."
- Review the full Separation and Distribution Agreement (Exhibit 10.1) for details on retained liabilities and asset transfers.
- Check the vesting schedule and terms of the 1,000,000 shares allocated to the 2020 Equity Incentive Plan.
- Monitor the status of the former CEO's Separation Agreement to ensure it has not been revoked within the seven-day window.